Endoscopic Band Ligation for Type 2 Diabetes Mellitus (ENDOBAND-DM)

Launched by EL KATIB HOSPITAL · Aug 5, 2025

Keywords

ClinConnect Summary

This clinical trial is testing a new procedure called Endoscopic Band Ligation (ENDOBAND-DM) to help people with type 2 diabetes better control their blood sugar. The procedure involves placing small bands in a specific part of the small intestine, called the duodenum, to encourage changes in the gut that may improve how the body manages blood sugar. Researchers want to see if this approach is safe and if it can help lower blood sugar levels over a period of 6 to 12 months.

Adults between 18 and 70 years old with type 2 diabetes who have moderately high blood sugar (measured by HbA1c levels between 7.5% and 10.5%) and a body weight in the overweight to obese range (BMI between 27 and 40) may be able to join. Participants must be taking oral diabetes medications but not insulin and be willing to undergo the endoscopic procedure (a minimally invasive test using a flexible tube) and attend follow-up visits. The study is not yet recruiting, and people with certain health conditions, previous gut surgeries, or pregnancies are not eligible. If you join, you will be closely monitored to see how the procedure affects your blood sugar and insulin levels.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 18 and 70 years
• • Confirmed diagnosis of type 2 diabetes mellitus
• • HbA1c between 7.5% and 10.5% at screening
• • Body Mass Index (BMI) between 27 and 40 kg/m²
• • Stable use of oral antidiabetic medications for ≥3 months prior to enrollment
• • Willingness to undergo endoscopic procedure and attend all follow-up visits
• • Signed informed consen
• Exclusion Criteria:
• • Use of insulin therapy
• • Previous bariatric or gastrointestinal surgery
• • Diagnosis of type 1 diabetes mellitus
• • Known gastrointestinal obstruction, ulcers, or active GI bleeding
• • History of pancreatitis, biliary disease, or abnormal anatomy in duodenum
• • Pregnancy or breastfeeding
• • Severe comorbidities (e.g., uncontrolled cardiovascular disease, advanced kidney or liver disease)
• • Use of GLP-1 receptor agonists within 3 months prior to enrollment
• • Inability or unwillingness to comply with the study protocol